Lv1
30 积分 2021-07-02 加入
Stereotactic body radiotherapy with sequential tislelizumab and chemotherapy as neoadjuvant therapy in patients with resectable non-small-cell lung cancer in China (SACTION01): a single-arm, single-centre, phase 2 trial
11天前
已完结
Estimated sensitivity profiles of lung cancer specific uncommon BRAF mutants towards experimental and clinically approved kinase inhibitors
3个月前
已关闭
Locoregionally Advanced, BRAF V600L–Positive, Mucosal Melanoma of the Hypopharynx Treated With a Combination of BRAF and MEK Inhibitors
3个月前
已完结
Concomitant medications during immune checkpoint blockage in cancer patients: Novel insights in this emerging clinical scenario
5个月前
已完结
OFCC1-ALK (Ointergenic: A20): A novel OFCC1 intergenic region-ALK fusion identified from a lung adenocarcinoma patient
5个月前
已完结
Trametinib and Hydroxychloroquine (HCQ) Combination Treatment in KRAS-Mutated Advanced Pancreatic Adenocarcinoma: Detailed Description of Two Cases
7个月前
已完结
Potential role of lymphocyte CD44 in determining treatment selection between stereotactic body radiotherapy and surgery for early-stage non-small-cell lung cancer
7个月前
已完结
BRAF V600E mutation and MET amplification as resistance pathways of the second-generation anaplastic lymphoma kinase (ALK) inhibitor alectinib in lung cancer
3年前
已完结
皖公网安备34019202002308
